Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer

  1. Sara Wedrén1,
  2. Cecilia Magnusson1,
  3. Keith Humphreys1,
  4. Håkan Melhus2,
  5. Andreas Kindmark2,
  6. Fredrik Stiger2,
  7. Maria Branting2,
  8. Ingemar Persson1,3,
  9. John Baron4 and
  10. Elisabete Weiderpass1,5,6
  1. 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 2Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 3Swedish Medical Products Agency, Uppsala, Sweden; 4Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire; 5Department of Etiological Research, The Cancer Registry of Norway, Oslo, Norway; and 6Samfundet Folkhalsan, Helsinki, Finland
  1. Requests for reprints:
    Elisabete Weiderpass, Department of Etiological Research, The Cancer Registry of Norway, 0310 Oslo, Norway. Phone: 35-840-845-3406; Fax: 47-22-45-13-70. E-mail: elisabete.weiderpass{at}kreftregisteret.no

Abstract

We investigated the association between polymorphism in the androgen receptor (AR) and vitamin D receptor (VDR) genes and breast cancer risk in a large population-based case-control study of genetically homogenous Swedish women. We successfully determined both AR CAGn and VDR An genotype in 1,502 women with invasive breast cancer and in 1,510 control women. We did not find any associations between AR or VDR microsatellite lengths and breast cancer when we used a priori determined cutoffs (≤21 or ≥22 repeats for AR and ≤18 or ≥19 for VDR) to define long and short alleles. There was statistically significant interaction between VDR genotype and parity, such that women with two short alleles had a halved risk for breast cancer, irrespective of parity, compared with nulliparous women with two long alleles. Homozygosity for the long VDR allele was associated with a more advanced clinical stage at diagnosis. In exploratory analyses, we determined cutoffs based on visual inspection of distributions of allele lengths among cases and controls and found that women carrying two alleles with <20 AR CAGn repeats had an increased risk for breast cancer, odds ratio of 1.67 (95% confidence interval, 1.17-2.38), compared with those with two alleles with ≥20 repeats. Women carrying two VDR alleles with <21 An were also at an increased risk, odds ratio of 1.26 (95% confidence interval, 1.04-1.51). Our data do not support major roles for AR or VDR polymorphism as breast cancer risk factors. However, we did find an interaction between VDR genotype and parity that remains to be corroborated. (Cancer Epidemiol Biomarkers Prev 2007;16(9):1775–83)

Footnotes

  • Grant support: U.S. Army, Department of Defense award no. DAMD17-98-1-8301 and Swedish Cancer Society grant 3915.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 15, 2007.
    • Received January 11, 2007.
    • Revision received June 1, 2007.
« Previous | Next Article »Table of Contents